British e-liquid manufacturer Riot Labs has recently cited a comprehensive Cochrane review to challenge proposed UK regulations on vape packaging. The review, which analysed 80 randomised trials involving nearly 30,000 smokers, found high-certainty evidence that nicotine e-cigarettes achieve higher six-month quit rates compared to nicotine replacement therapies such as patches and gum.
Evidence Versus Perception
Riot Labs' CEO Ben Johnson emphasised the gap between public perception and scientific evidence regarding vaping products. The company expressed concern that the Department of Health and Social Care’s proposed restrictions on vape packaging, appearance, and retail displays could inadvertently undermine smokers’ motivation to switch from cigarettes to vaping.
Regulatory Recommendations and Industry Response
The Cochrane review authors recommend that consumers seeking to quit smoking by using e-cigarettes should opt for products tested and approved by their country’s regulatory authorities. Riot Labs plans to reference these findings in its formal response to the government consultation on vape packaging, which closes on 2 October. The company advocates for a three-tier retailer licensing system, including enhanced requirements for outlets accessible to children and a distinct category for specialist vape retailers with age restrictions.
While Riot Labs highlights these scientific findings, it is important to note that tobacco and nicotine products remain age-restricted and carry inherent health risks. The debate over vape packaging regulations reflects ongoing tensions between public health objectives and industry interests.
For further insights on tobacco and nicotine product regulation, trade developments, and community perspectives, visit https://cigarettesandbaccy.com.
Adult editorial disclaimer: Tobacco and nicotine products are age-restricted and harmful.